A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient’s body and responses to treatment.
Previous versions of the approach, which relies on monitoring levels of tumor DNA circulating in the blood, have required cumbersome and time-consuming steps to customize it to each patient or have not been sufficiently sensitive.
Now, researchers at the Stanford University School of Medicine have devised a way to quickly bring the technique to the clinic. Their approach, which should be broadly applicable to many types of cancers, is highly sensitive and specific. With it they were able to accurately identify about 50 percent of people in the study with stage-1 lung cancer and all patients whose cancers were more advanced.
“We set out to develop a method that overcomes two major hurdles in the circulating tumor DNA field,” said Maximilian Diehn, MD, PhD, the CRK Faculty Scholar and assistant professor of radiation oncology. “First, the technique needs to be very sensitive to detect the very small amounts of tumor DNA present in the blood. Second, to be clinically useful it’s necessary to have a test that works off the shelf for the majority of patients with a given cancer.”
The researchers describe their findings in a paper published online April 6 in Nature Medicine. Diehn shares senior authorship with Ash Alizadeh, MD, PhD, assistant professor of medicine. Postdoctoral scholars Aaron Newman, PhD, and Scott Bratman, MD, PhD share lead authorship.
“We’re trying to develop a general method to detect and measure disease burden,” said Alizadeh, a hematologist and oncologist. “Blood cancers like leukemias can be easier to monitor than solid tumors through ease of access to the blood. By developing a general method for monitoring circulating tumor DNA, we’re in effect trying to transform solid tumors into liquid tumors that can be detected and tracked more easily.”
Even in the absence of treatment, cancer cells are continuously dividing and dying. As they die, they release DNA into the bloodstream, like tiny genetic messages in a bottle. Learning to read these messages — and to pick out the one in 1,000 or 10,000 that come from a cancer cell — can allow clinicians to quickly and noninvasively monitor the volume of tumor, a patient’s response to therapy and even how the tumor mutations evolve over time in the face of treatment or other selective pressures.
“The vast majority of circulating DNA is from normal, non-cancerous cells, even in patients with advanced cancer,” Bratman said. “We needed a comprehensive strategy for isolating the circulating DNA from blood and detecting the rare, cancer-associated mutations. To boost the sensitivity of the technique, we optimized methods for extracting, processing and analyzing the DNA.
The researchers’ technique, which they have dubbed CAPP-Seq, for Cancer Personalized Profiling by deep Sequencing, is sensitive enough to detect just one molecule of tumor DNA in a sea of 10,000 healthy DNA molecules in the blood. Although the researchers focused on patients with non-small-cell lung cancer (which includes most lung cancers, including adenocarcinomas, squamous cell carcinoma and large cell carcinoma), the approach should be widely applicable to many different solid tumors throughout the body. It’s also possible that it could one day be used not just to track the progress of a previously diagnosed patient, but also to screen healthy or at-risk populations for signs of trouble.
Tumor DNA differs from normal DNA by virtue of mutations in the nucleotide sequence. Some of the mutations are thought to be cancer drivers, responsible for initiating the uncontrolled cell growth that is the hallmark of the disease. Others accumulate randomly during repeated cell division. These secondary mutations can sometimes confer resistance to therapy; even a few tumor cells with these types of mutations can expand rapidly in the face of seemingly successful treatment.
Different from patient to patient
“Cancer is a genetic disease,” Alizadeh said. “But unlike Down syndrome, for example, which has a single dominant cause, for most cancers it’s very difficult to identify any one particular genetic aberration or mutation that is found in every patient. Instead, each cancer tends to be genetically different from patient to patient, although sets of mutations can be shared among patients with a given cancer.”
The Latest on: Cancer blood test
via Google News
The Latest on: Cancer blood test
- Springing for canceron November 13, 2020 at 12:00 am
You can get away with anything,” an older friend of mine once told me, “if you’re wearing an expensive watch.” ...
- The mysterious rise of colon cancer among Gen-Xers and Millennialson November 12, 2020 at 5:50 pm
As colon cancer rates drop among older adults, younger generations are seeing a troubling trend. CLEVELAND — When the world lost actor Chadwick Boseman in August, his death from colon cancer exposed a ...
- Pre-screening key to combating prostate canceron November 12, 2020 at 2:35 pm
Dr Christopher Hobaugh, a urologist with Kelsey Sebold in The Woodlands, says focusing in the early warning signs of testicular and prostate cancers can help catch them before the conditions morph ...
- Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101on November 12, 2020 at 1:19 pm
Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2DSOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: NKTX), a clinical-stage biopharmaceutical company ...
- Israeli blood test offers better choices to fight canceron November 12, 2020 at 5:59 am
The most promising cancer therapies often help some patients but not others, frustrating some cancer sufferers and their doctors. With the clock ticking on people’s lives, physicians often do not have ...
- AstraZeneca's cancer drug disappoints as potential COVID-19 treatmenton November 12, 2020 at 5:50 am
AstraZeneca's blood cancer treatment, Calquence, failed to improve survival rates and prevent lung failure in patients hospitalised with symptoms of COVID-19, the drugmaker said on Thursday, citing ...
- Study shows potential of new pinprick blood test for diagnosing HPV-related cancerson November 12, 2020 at 1:15 am
A potential breakthrough in the early detection of the neck, head and anal cancers linked to human papilloma viruses has emerged.
- Rare Event: Iatrogenic Injury During Cervical Cancer Screeningon November 10, 2020 at 3:34 am
A new study finds that in rare instances, women with invasive cervical cancer experience medical complications during their diagnostic workup.
- Large Study Shows That A Simple Blood Test Can Accurately Differentiate Between Benign and Malignant Lesionson November 9, 2020 at 4:04 am
A large, landmark study published in the American Cancer Society’s prestigious journal ‘Cancer Cytopathology’ shows that a simple non-invasive blood test (liquid biopsy) can accurately differentiate ...
- Women with ovarian cancer can FINALLY be diagnosed with a simple blood test given by GPson November 7, 2020 at 2:11 pm
The test measures levels in the blood of a protein called cancer antigen 125, or CA125, found on the surface of some cancers. Exactly what a raised level means hasn't been clear - until now.
via Bing News